Johannsen, Manfred <br/><br/>
Can tyrosine kinase inhibitors be discontinued in patients with metastatic renal cell carcinoma and a complete response to treatment? A multicentre, retrospective analysis.  [electronic resource] 

 -  European urology  Jun 2009 
 - 1430-8 p.  digital 
<br/><br/> Publication Type: Journal Article; Multicenter Study 
<br/><br/><label>ISSN: </label>1873-7560 
<br/><br/><label>Standard No.: </label>10.1016/j.eururo.2008.10.021  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Aged<br/>Antineoplastic Agents--administration & dosage<br/>Benzenesulfonates--administration & dosage<br/>Carcinoma, Renal Cell--drug therapy<br/>Chemotherapy, Adjuvant<br/>Dose-Response Relationship, Drug<br/>Drug Administration Schedule<br/>Female<br/>Follow-Up Studies<br/>Humans<br/>Indoles--administration & dosage<br/>Kidney Neoplasms--drug therapy<br/>Magnetic Resonance Imaging--methods<br/>Male<br/>Middle Aged<br/>Neoplasm Metastasis<br/>Neoplasm Recurrence, Local--mortality<br/>Neoplasm Staging<br/>Nephrectomy--methods<br/>Niacinamide--analogs & derivatives<br/>Phenylurea Compounds<br/>Protein Kinase Inhibitors--administration & dosage<br/>Protein-Tyrosine Kinases--antagonists & inhibitors<br/>Pyridines--administration & dosage<br/>Pyrroles--administration & dosage<br/>Retrospective Studies<br/>Risk Assessment<br/>Sorafenib<br/>Sunitinib<br/>Survival Analysis<br/>Tomography, X-Ray Computed--methods<br/>Treatment Outcome<br/>Withholding Treatment